# Repligen Q3 2026 Earnings Beat

> Repligen reports $209.3m Q3 revenue with 12.5% organic growth and BioLife acquisition integration progress.
- Title: Repligen Q3 2026 Earnings Beat · The Motley Fool | Shortify
- Summary: Repligen reports $209.3m Q3 revenue with 12.5% organic growth and BioLife acquisition integration progress. Repligen's Q3 2026 revenue reached $209.3 million…
- Keywords: repligen, rgen, q3 2026, earnings call, bio life, chromatography, proteins, analytics, filtration, cell therapy, cdmo, biopharma
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/10/27/repligen-rgen-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-10-27T15:39:21+00:00
- Read time: 1 min
- Topics: repligen, rgen, q3 2026, earnings call, bio life, chromatography, proteins, analytics, filtration, cell therapy, cdmo, biopharma
## Q3 Revenue
Repligen reported total revenue of $209.3 million for Q3 2026.
## Organic Growth
12.5% organic growth driven by chromatography and proteins franchises.
## BioLife Acquisition
Acquired BioLife Solutions for $114 million pro forma 2026 revenue.
## Q3 Earnings
Adjusted fully diluted EPS of $0.53, up from $0.46 in prior year.
## Chromatography Growth
Over 50% revenue growth from Opus columns and large scale columns.
## Proteins Growth
Over 40% revenue growth from ligands, growth factors, and custom resins.
## Analytics Growth
20% revenue growth despite difficult year-over-year comparison.
## Filtration Decline
11% revenue decline from ACF headwind and PolyMem divestment.
## Capital Equipment
Mid-teens growth year over year with highest orders quarter in five years.
## Services Growth
Greater than 20% growth with systems under contract increasing 40%.
## China Growth
Greater than 40% revenue growth with successful technology transfers.
## Cell Therapy Growth
Nearly 30% revenue growth supporting BioLife integration.
## Operating Margin
15.9% adjusted operating margin, up 170 basis points year over year.
## EBITDA Margin
20.9% adjusted EBITDA margin targeting 30% by 2030.
## Pro Forma Cash
Pro forma cash balance over $300 million after $550 million BioLife deployment.
## Year 1 Accretion
At least $0.05 per share expected in 2027 from operating expense synergies.
## Key takeaway

Repligen's Q3 2026 revenue reached $209.3 million with 12.5% organic growth, driven by chromatography and proteins, and BioLife acquisition integration delivering first-year operating expense synergies.